Tissue Factor Pathway Inhibitor: Regulation Of Its Inhibitory Activity By Phospholipid Surfaces?

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue , 1996, Pages 89-97

  Lindhout, Théo ^a   Salemink, Irene ^a   Valentin, Sanne ^b   Willems, George M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Factor X activation; Flow reactor; Phospholipids; TFPI; Tissue factor

Indexed keywords

BLOOD CLOTTING FACTOR 10; PHOSPHOLIPID; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

BLOOD CLOTTING; CONFERENCE PAPER; HUMAN; PRIORITY JOURNAL;

BINDING SITES; ENZYME ACTIVATION; FACTOR XA; HUMANS; LIPID BILAYERS; LIPOPROTEINS; MACROMOLECULAR SUBSTANCES; PEPTIDE FRAGMENTS; PHOSPHATIDYLCHOLINES; PHOSPHOLIPIDS; PROTEIN BINDING; SURFACE PROPERTIES;

EID: 0029960581     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217289     Document Type: Article

References (23)

1. Broze GJ, Jr.: Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coag Fibrinol 1995; 6: 7-13.
2. Wun TC, Kretzmer KK, Girard TJ. Miletich JP. Broze GJ, Jr.: Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001-6004.
3. Huang ZF, Wun TC. Broze GJ. Jr.: Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993; 268: 26950-26955.
4. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG. Miletich JP, Broze GJ, Jr.: Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-520.
5. Enjyoji K, Miyata T, Kamikubo Y, Kato H: Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site. Biochemistry 1995: 34: 5725-5735.
6. Valentin S, Nordfang O, Bregengard C, Wildgoose P: Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coag Fibrinol 1993; 4: 713-720.
7. Nordfang O, Bjorn SE, Valentin S, Nielsen LS, Wildgoose P, Beck TC. Hedner U: The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry 1991:30: 10371-10376.
8. Pedersen AH, Nordfang O, Norris F, Wiberg FC, Christensen PM. Moeller KB, Meidahl Pedersen J, Beck TC, Noms K, Hedner U, et al.: Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. J Biol Chem 1990; 265: 16786-16793.
9. Petersen JG, Meyn G, Rasmussen JS, Petersen J, Bjorn SE, Jonassen I, Christiansen L, Nordfang O: Characterization of human tissue factor pathway inhibitor variants expressed in Saccharomyces cerevisiae. J Biol Chem 1993; 268: 13344-13351.
10. Wesselschmidt R. Likert K, Huang Z, MacPhail L, Broze GJ, Jr.: Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coag Fibrinol 1993;4:661-669.
11. Valentin S, Lamkjer A, Ostergaard P, Nielsen JI, Nordfang O: Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res 1994; 75: 173-183.
12. Bregengaard C, Nordfang O, Ostergaard P. Petersen JG, Meyn G. Diness V, Svendscn O. Hedner U: Pharmacokinetics of full length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits. Thromb Haemost 1993; 70: 454-457.
13. Sandset PM. Abildgaard U, Larsen ML: Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-813.
14. Valentin S, Schousboe I: Factor Xa enhances the binding of tissue factor pathway inhibitor to acidic phospholipids. Thromb Haemostas 1996; 75: 796-800.
15. Lindhout T, Franssen J, Willems G: Kinetics of the inhibition of tissue factor-factor Vila by tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 910-915.
16. Giesen PLA, Willems GM. Hemker HC, Hermens WT: Membrane-Mediated Assembly of the Prothrombinase Complex. J Biol Chem 1991; 266: 18720-18725.
17. Billy D, Speijer H. Willems GM, Hemker HC, Lindhout T: Prothrombin activation by prothrombinase in a tubular flow reactor. J Biol Chem 1995; 270: 1029-1034.
18. Contino P. Repke D, Nemerson Y: A continuous flow reactor system for the study of blood coagulation. Thromb Haemost 1991; 66: 138-140.
19. Cuypers PA, Corsel JW, Janssen MP, Kop JJM, Hermens WT, Hemker HC: The adsorption of prothrombin to phosphatidylserine multilayers quantitated by ellipsometry. J Biol Chem 1983; 258: 2462-2431.
20. Corsel JW, Willems GM, Kop JMM, Cuypers PA, Hemiens WT: The role of intrinsic binding rate and transport rate in the adsorption of prothrombin, albumin, and fibrinogen to phospholipid bilayers. J Colloid Interface Sci 1986; 111: 544-554.
21. Andree HAM, Nemerson Y: Tissue factor: regulation of activity by flow and phospholipid surfaces. Blood Coag Fibrinol 1995; 6: 189-197.
22. Gemmell CH, Broze GJ, Jr. Turitto VT, Nemerson Y: Utilization of a continuous flow reactor to study the lipoprotein-associated coagulation inhibitor (LACI) that inhibits tissue factor. Blood 1990; 76: 2266-2271.
23. Hamamoto T, Yamamoto M, Nordfang O, Petersen JG, Foster DC, Kisiel W: Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor Vlla-tissue factor complexes on cell surfaces. J Biol Chem 1993; 268: 8704-8710.